Claude did not invent scorpion antivenom
What happened
An investment research firm called Citrini Research partnered with Anthropic to test if an unreleased version of the AI model Claude could invent scorpion antivenom. The AI tool failed to deliver a drug candidate despite generating some promising starting points. Experts told The Verge that the output was far from a usable antivenom. Citrini admitted it lacked deep AI and biology expertise but pushed ahead with the experiment anyway.
Why it matters
This experiment exposes the limits of current AI in drug discovery, especially for complex tasks like designing antivenoms. It undercuts marketing claims that AI alone can rapidly invent lifesaving drugs without expert guidance. Investors and founders should be cautious about overhyping AI drug development capabilities. For now, AI remains a tool that can aid discovery but cannot replace the nuanced biology knowledge and rigorous testing required to develop effective medicines.
What to watch next
Keep an eye on how AI companies calibrate their drug discovery claims going forward. Expect more public tests of AI on complex biomedical problems with honest assessments by domain experts. The combination of AI with domain expertise and laboratory validation will remain essential. Watch for new announcements from Anthropic and others outlining realistic AI roles in biopharma pipelines, not standalone miracles.
AI Quick Briefs Editorial Desk